Targeting hepatocyte growth factor/c‐mesenchymal–epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies
Jianqing Yu(Wuhan University), Paul B.S. Lai(Chinese University of Hong Kong), George G. Chen(Chinese University of Hong Kong)
Cited by 34
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial
|The Lancet|2004|895
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments
|Proceedings of the National Academy of Sciences|2015|818
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients
|Proceedings of the National Academy of Sciences|2015|770
Immediate and long-term impact of the COVID-19 pandemic on delivery of surgical services
|British journal of surgery|2020|719